389MO Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in patients (pts) with locally advanced (LA) esophageal squamous cell carcinoma (ESCC): RATIONALE-306 subgroup analysis
Titel:
389MO Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in patients (pts) with locally advanced (LA) esophageal squamous cell carcinoma (ESCC): RATIONALE-306 subgroup analysis
Auteur:
Van Cutsem, E. Xu, J. Raymond, E. Hubner, R. Yoon, H. Kato, K. Wyrwicz, L.S. Tougeron, D. Park, S.R. Fonseca, P. Jimenez Kojima, T. Ishihara, R. Avallone, A. Cid, R.A. Pazo Xu, S. Yan, S. Shi, J. Kong, X. Lordick, F.